Paris · Pre-Seed–Late Stage · 89 people tracked
Also known as SOFINNOVA PARTNERS SAS
Investment thesis
Sofinnova Partners invests in breakthrough innovations addressing major health and environmental challenges. Active across the entire life sciences value chain from seed to later-stage, it focuses on healthcare and sustainability, backing entrepreneurs transforming biopharma, medtech, digital medicine, agriculture and industrial processes with cutting-edge science. The firm operates seven investment strategies, ranging from its flagship early-stage biopharma/medtech Capital fund to in-house accelerators (MD Start, Biovelocita), a Crossover growth-stage fund, an Industrial Biotech strategy spanning agriculture, chemicals, food and materials, the Telethon strategy focused on Italian science, and a Digital Medicine strategy at the intersection of biology, data and computation. It emphasizes long-term 'Partners for Life' relationships built on trust.
Source: firm website, verified Aug 26, 2026.
Team · 89 people
from the firm's website & curated & public directories
Founder mafia
The Sofinnova Partners mafia →8 people who came through Sofinnova Partners went on to found or lead other companies.
What they invest in
from 97 of 174 portfolio companiesBiotech ×78Healthtech ×52Medical Devices ×29AI & Machine Learning ×15Deep Tech ×14New Materials ×11Cleantech ×7Digital Health ×7
HQs:United States×28France×9United Kingdom×4Italy×4Belgium×1Netherlands×1
Who they back
founder profiles across 25 portfolio companiesFounding team size:solo founder×112 founders×93 founders×24+ founders×3
Where their founders studiedfrom 17 founders with education data
École Polytechnique ×2INSEAD ×2Northwestern University ×2The University of Texas at Austin ×2
Where their founders worked beforefrom 18 founders with career history
University of Colorado Boulder ×3Dbv Technologies ×2
Investments · 174 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 52024 · 42023 · 72021 · 12019 · 32018 · 22016 · 32014 · 129 dated
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)Mikhail Kalinichev(Executive Officer)Jean-Philippe Rocher(Executive Officer)Robert Lutjens(Executive Officer)Timothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Co-investorsNew Enterprise Associates (NEA)ACORN BIOVENTURESSR One Capital Management
Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options.
BiotechHealthtech
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsHealthCapNovo Holdings
BiotechGaithersburg, US
Douglas A Doerfler(Executive Officer, Director)Madhusudan V Peshwa(Executive Officer)Ronald E Holtz(Executive Officer, Director)Thomas Ross(Executive Officer)Arthur Mandell(Director)Sinclair Dunlop(Director)
BiotechSouth San Francisco, US
Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)Brendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)Kristen Gafric(Executive Officer)
Co-investorsForesite Capital
BioCorteX develops personalized therapeutics using a microbiome knowledge graph and proprietary biology emulation platform to tailor drug treatments for diverse populations.
AI & Machine LearningBiotechDigital HealthMedical Devices
Co-investorsHoxton VenturesDraper Associates
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)
Co-investorsJeito CapitalSanofi VenturesVIVES PartnersApollo Health VenturesSixty Degree Capital
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)
Co-investorsMonograph Capital PartnersForbion
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsIndaco Venture PartnersRoche Venture FundAbbVieJDRF T1D Fund
Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development.
AI & Machine LearningBiotechDeep Tech
Marty BurkeBartosz GrzybowskiMichael Foley(CEO)Jana Jensen(COO)
Co-investorsKhosla VenturesCornucopian Capital ManagementIllinois Ventures
Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners.
BiotechDeep TechDigital HealthHealthtech
Dr. Lucia Faccio(Chief Executive Officer)inDr. Julianne Smith(Chief Development Officer)Dr. Simon Hawkins(VP Clinical Development)Dr. Smaragda Angelidou(Responsabile CMC)Dr. Mary Wang(Patient Engagement Director)Emanuela Balzo(VP of Finance)
Co-investorsCDP Venture CapitalIndaco Venture PartnersXGEN Venture
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)Daniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsBroadview VenturesApollo Health Ventures+ND Capital4see Ventures
HighLife develops a transcatheter mitral valve replacement (TMVR/TSMVR) technology for patients with moderate to severe mitral regurgitation, implanted in a beating heart while preserving the native valve structure.
BiotechHealthtechMedical DevicesParis, FR
Georg Börtlein(Founder)Malek Nasr(Founder)Rüdiger Lange(Founder (Heart Surgeon))Nicolo Piazza(Founder (Interventional Cardiologist))Stefan Pilz(CEO)Jose Calle Gordo(Chairman)
Co-investorsAndera PartnersUS Venture Partners
Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.
AI & Machine LearningBiotechHealthtech
David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in
Co-investorsREDMILE
Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors.
BiotechHealthtechLondon, GB
John Maher(Founder)
Co-investorsVulpes Investment ManagementEpidarex Capital
Moon Surgical develops the Maestro robotic surgery system, a digital surgical robotics platform used by surgeons to perform procedures.
HealthtechMedical DevicesRoboticsParis, FR
Brice Gayet(Founder)Anne Osdoit(Chief Executive Officer)inEric Ermenault(Chief Commercial Officer)inAnne Renevot(Chief Financial Officer)inViola Fleig(Chief Operations Officer)inDavid Noonan(Chief Technology Officer)in
Co-investorsNVIDIACathay HealthNVentures
NanoPhoria is a life sciences company that raised an €83.5 million Series A round.
BiotechDeep TechMedical Devices
Daniele CatalucciMichele IafiscoAlessio AlognaClaudio De Luca
Co-investorsXGEN VentureCDP Venture CapitalEuropean Innovation Council Fund
SafeHeal is a medical device manufacturer developing anastomosis protection devices for colorectal surgery.
BiotechDigital HealthHealthtechMedical DevicesFrance, FR
Chris Richardson(President & CEO)Karl Blohm(VP, International)inScott DePierro(VP, US Operations)inMarcos Velez-Duran(VP, Regulatory Affairs and Quality)inBrent Metzler(CFO)Michael Augelli(VP, R&D, Manufacturing)in
Co-investorsAsabys Partners
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsLongwood FundOxford Science EnterprisesSV Health Investors
BiotechWaltham, US
KARIM HELMY(Director)MARC DE GARIDEL(Executive Officer, Director)SYLVIE GREGOIRE(Director)TYRELL RIVERS(Director)RAM AIYAR(Executive Officer)
BoardAARON KANTOFF(Director)
Board seatGraziano Seghezzi· per SEC Form D
Co-investorsAndera PartnersScion Life Sciences
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)Steve Anheier(Executive Officer)
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+2 more
BiotechNew York, US
Joern Aldag(Executive Officer, Director)Reinhard Kandera(Executive Officer, Director)Paul-Henri Lambert(Director)Michael Kelly(Director)Julie O'Neill(Director)Sander van Deventer(Director)
Board seatGraziano Seghezzi· per SEC Form D
Co-investorsThird Rock Ventures
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatMaina Bhaman· per SEC Form D
Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLC+2 more
RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.
BiotechHealthtechMedical DevicesHayward, US
Samuel Mazin(Executive Officer, Director)Akshay Nanduri(Executive Officer, Director)
BoardJay Watkins(Director)
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPPfizer Venture InvestmentsSonder CapitalVenrockSonder Futures
BiotechNew York, US
Masoud Tavazoie(Chief Scientific Officer)David Darst(Chief Operating Officer)Isabel Kurth(Vice President - Research)
BoardShahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)
Board seatAntoine Papiernik Papiernik· per SEC Form D · $33M raise · filed Jun 2016
Co-investors+ND Capital
Shockwave Medical develops intravascular lithotripsy (IVL) catheter systems used to treat calcified cardiovascular disease, marketed to interventional cardiologists and vascular specialists.
HardwareHealthtechMedical DevicesFremont, US
Daniel Hawkins(Executive Officer, Director)inTodd J. Brinton(Director)inIsaac(President)
BoardJay Watkins(Director)inAntoine Papiernik(Director)inFrederic H. Moll(Director)
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investorsSonder CapitalVenrockSectoral Asset Management
Co-investorsNeva Sgr.XGEN Venture
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersClaret Capital PartnersMedicxiSamsara BioCapitalTruffle Capital
Actithera develops radioligand therapies (RLT) for cancer, using proprietary molecular design and chemistry to create compounds that concentrate in tumors while sparing healthy tissue.
BiotechHealthtech
Darshan Dalal(Chief Medical Officer)
Co-investorsHadean VenturesM Ventures4BIO CapitalBioqube Ventures
Afyren produces bio-based organic acids derived from fermentation of non-food biomass to replace petroleum-derived molecules in consumer products and industrial applications.
BiotechCircular EconomyCleantech
Nicolas Sordet(Co-founder)Jérémy Pessiot(Co-founder)Jérémy Pessiot⚡(Founder)in
Co-investorsSupernova Invest
Alia Therapeutics is a gene editing company developing genetic medicines aimed at curing genetic diseases.
BiotechDeep TechHealthtech
Co-investorsIndaco Venture Partners
Co-investorsAndera PartnersCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersLSP (Life Sciences Partners)
Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043).
BiotechHealthtech
Co-investorsAndera PartnersM VenturesNovartis Venture FundPfizer Venture InvestmentsRA CapitalSV Health Investors
Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software.
AI & Machine LearningBiotechDeep TechFoodTechNew MaterialsSeattle, US
Alexandre Zanghellini(Co-Founder & Chief Executive Officer)inEric Althoff(Executive Officer, Director, Promoter)David BakerBill Baum(Director)inAndrew Ban(Executive Officer)Daniela Grabs(Executive Officer)
Co-investorsCirculate CapitalSustainable Conversion VenturesFall Line CapitalOS FundUniversal Materials Incubator
Co-investorsKurma PartnersM VenturesSR One Capital Management
Avantium develops innovative plant-based materials designed to replace fossil fuel-derived chemicals and advance the transition to a circular economy.
Circular EconomyCleantechNew MaterialsNetherlands, NL
Co-investorsAster CapitalCapricorn Venture PartnersNV NOMPMVSignet Healthcare Partners
Bioptimus is an AI-first biotech company developing a universal AI foundation model that connects biology across scales, from molecules and cells to tissues and whole organisms, to support biomedical research and innovation.
AI & Machine LearningBiotechDigital HealthHealthtechParis, FR
Eric Durand(Founder)Felipe Llinares-López(Co-founder & VP of AI)Rodolphe Jenatton(Co-founder & CTO)Zelda Mariet(Co-founder & VP of Research)Jean-Philippe Vert(Co-founder & CEO)inDavid Cahané(Co-founder & General Manager)
Co-investorsAndera PartnersCathay InnovationFELIX CAPITALFrstHeadlineHeadline Growth Management, LLC+3 more
Co-investorsEuropean Circular Bioeconomy Fund
Biotalys develops protein-based biocontrol products for crop protection, giving farmers tools to prevent crop loss and extend post-harvest protection while reducing food waste.
AgTechBiotechFoodTechGhent, BE
Co-investorsAgri Investment FundPMV
Co-investorsCDP Venture CapitalIndaco Venture Partners
Borea Therapeutics develops therapies for patients with genetic or chronic diseases using next-generation viral vectors.
BiotechDeep TechHealthtech
Calliditas develops novel therapeutics for orphan indications, with an initial focus on renal and hepatic rare diseases.
BiotechHealthtech
Co-investorsIndustrifondenKreos Capital
Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering.
BiotechHealthtech
Branden Moriarity(Scientific Co-founder)Catherine Bollard(Scientific Co-founder)
Co-investorsAstellas Venture Management LLC
CelluComp manufactures Curran, a patented bio-based platform derived from cellulose nanofibres extracted from vegetable waste, used to add strength and barrier properties to pulp and other materials as a replacement for plastics and PFAS.
Circular EconomyCleantechNew Materials
Advancing clinical candidates for cardiovascular, metabolic and kidney diseases.
BiotechCincinnati, US
Marc de Garidel(Executive Officer, Director)
Co-investorsSofinnova Ventures
Cambridge, US
ENEJ KUSCER, PH.D.(Executive Officer)PETER VAN VLASSELAER, PH.D.(Director)HENRIJETTE RICHTER, PH.D.(Director)BERNARDUS MACHIELSE(Director)LUCAS DE BREED(Director)DAVID DE GRAAF, PH.D.(Executive Officer, Director)
Co-investorsMission Biocapital
Co-investors415 Capital
CorVent Medical develops medical ventilators, including the RESPOND ventilator, that provide ICU-standard respiratory support for acute and post-acute patients.
HardwareHealthtechMedical DevicesFargo, US
Murphy Travis(Executive Officer)Jeremy Nelson(Executive Officer)Richard S. Walsh(Executive Officer, Director)John O'Mahony(Executive Officer)Rob Faulkner(Director)Lukas Geunther(Director)
CorWave is a medical device company developing heart-assist pumps designed as a physiological solution for patients with heart failure.
Deep TechHealthtechMedical Devices
Co-investorsYsios Capital
Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699.
BiotechHealthtech
Co-investorsAndera PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalQuan CapitalAvlar BioVentures+1 more
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform.
AI & Machine LearningBiotechDigital HealthHealthtech
Paloma Cejas(Founder, Head of Translational Research)Rémy Nicolle(Founder, Senior Advisor Computational Biology)
Co-investorsHitachi VenturesKima VenturesLifeX Ventures
An AI radiology platform that automates the reporting process and hosts 80+ leading imaging AI vendors.
Co-investorsMeridian Health Ventures
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols.
BiotechClimate TechNew MaterialsBoulder, US
Matthew Lipscomb(Director)Josh Yelen(Executive Officer)Jim Flatt(Executive Officer, Director)
BoardJosko Bobanovic(Director)Rob van der Meij(Director)Alastair Cooper(Director)
Co-investorsBreakthrough Energy VenturesBoulder VenturesCapricorn Venture Partners
Elicit Plant develops crop treatments based on phytosterols, natural plant growth regulators that strengthen plants' natural defense mechanisms and improve crop resilience for agricultural use.
AgTechBiotechClimate Tech
Olivier Goulay(Founder)in
Co-investorsEuropean Circular Bioeconomy Fund
Endoron Medical develops transcatheter anchoring and sealing devices for aortic procedures, including Aortodock (a nitinol docking system to stabilize transcatheter valves in low-calcium aortic regurgitation and stenosis anatomies) and Aortoseal (a multi-stapling fixation and sealing system for endovascular aneurysm repair grafts).
HardwareHealthtechMedical Devices
EnginZyme develops a patented enzyme immobilisation technology to create stable, bespoke biocatalysts for use in multi-step enzymatic reactions.
BiotechCleantechNew Materials
Co-investorsIndustrifondenNavigare Ventures
ENYO Pharma is a clinical-stage biopharmaceutical company developing therapeutics for patients with impaired kidney function.
BiotechMedical Devices
Co-investorsAndera PartnersOrbiMedBpifrance
F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.
BiotechHealthtech
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSunstone Capital+3 more
Freya Biosciences is a clinical-stage immunology company developing therapies targeting inflammation and immune dysregulation in conditions affecting women, including infertility and pregnancy-related dysbiosis.
BiotechFemTechHealthtech
Co-investorsAngelini VenturesIndaco Venture PartnersOMX Ventures
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst InvestorsFidelity Investments+5 more
GFBiochemicals produces plant-based chemicals, specializing in levulinate technologies and derivatives under its RE:CHEMISTRY brand.
BiotechCleantechNew Materials
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalAgent Capital+1 more
Co-investorsAsabys Partners
Princeton, US
Dylan Porges(Mr. Porges is a Director.)Ayooluwa Oguntola(Mr. Oguntola is CEO and a Director.)
HotSpot Therapeutics is a drug discovery company developing small-molecule allosteric medicines by targeting "natural hotspots" — regulatory on/off switches on proteins.
AI & Machine LearningBiotechHealthtech
Co-investorsAtlas VentureB Capital GroupB4 CapitalMRL Ventures FundSolasta VenturesSR One Capital Management
Ingenix builds an AI "Reasoning Engine" using an approach it calls Modality Fusion to integrate biological data across modalities and scales.
AI & Machine LearningBiotechDeep Tech
Adam Dancewicz(Founder)
Co-investorsInovo VCOTB VenturesIFC
Co-investorsAndera Partners
Inspirna is a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, including oral small molecules and biologics that target newly discovered drivers of metastasis in common cancers such as colorectal, non-small cell lung, and endometrial cancer.
BiotechHealthtechNew York, US
Co-investorsStart CapitalVivo CapitalNovo HoldingsSands Capital Ventures
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Samsara BioCapital
iOmx is a clinical-stage biotech company developing targeted cancer immunotherapies for common solid tumor indications, translating tumor immune evasion biology into biomarker-enabled drug programs.
BiotechHealthtech
Co-investorsM Ventures
The National Kidney Foundation is a nonprofit organization focused on kidney disease, providing patient education, emotional support, and resources for patients, families, living donors, and transplant recipients.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesEpidarex CapitalRoche Venture FundScottish National Investment Bank
Kiro is a health technology company that transforms healthcare data into actionable intelligence for patients and healthcare providers.
AI & Machine LearningDigital HealthHealthtech
Co-investorsKima Ventures
LimFlow develops a medical device system for the treatment of chronic limb-threatening ischemia.
HealthtechMedical Devices
Co-investorsLongitude Capital
HealthtechPlymouth, US
Dan Sachs(Director)Peter Crosby(Executive Officer, Director)Jason Hannonin
BoardManus Rogan(Director)Antoine Papiernik(Director)
Co-investorsFountain Healthcare PartnersAlly Bridge GroupGilde HealthcareViking Global Investors
May Health develops the Anavi procedure, a one-time outpatient treatment using targeted ovarian ablation to restore ovulation in people with Polycystic Ovary Syndrome (PCOS).
FemTechHealthtechMedical Devices
Anne Morrisseyin
Co-investorsBpifrance
Meiogenix develops a proprietary recombination technology that targets meiotic recombination to accelerate genetic gain and variety development in crops.
AgTechBiotechDeep Tech
Ricardo Garcia de Albain
Co-investorsGenoa VenturesKurma PartnersCasdin Capital
Micropep develops micropeptide-based crop protection and crop stimulation products for farmers, using a discovery platform that combines artificial intelligence, bioproduction, and delivery technologies.
AgTechAI & Machine LearningBiotechToulouse, FR
Co-investorsSupernova InvestZebra Impact VenturesFall Line Capital
Microphyt develops natural ingredients derived from microalgae using biomimetic technology at the intersection of life sciences and bio-processes.
BiotechNew MaterialsWellness & Fitness
Co-investorsSupernova Invest
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)
Co-investorsEpidarex CapitalRoche Venture FundBioGeneration VenturesScottish National Investment Bank
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsRoche Venture FundSR One Capital Management
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsAlexandria+3 more
Muna Therapeutics is a biotechnology company that discovers and develops therapies aimed at slowing or stopping neurodegenerative diseases, including Alzheimer's and Parkinson's.
BiotechLongevity
Rita Balice-Gordon(Founder)in
Co-investorsDroia VenturesSanofi VenturesV-Bio Ventures
Myricx is a biotech company developing a new class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferase (NMT) enzymes, aimed at treating cancer.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon Capital PartnersNovo Holdings
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)
Co-investorsMission BiocapitalDementia Discovery FundMission Bay Capital
BiotechJackson, US
Irene Griswold-Prenner(Executive Officer, Director)
BoardZach Hall(Director)Ephraim Heller(Director)William McDowell(Director)Regis Kelly(Director)
Co-investorsSV Health InvestorsDementia Discovery Fund
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)Chris Guiffre(Executive Team)Alan P. Watt(Executive Team)Jyothis George(Chief Medical Officer)Nick Clarke(Executive Team)
Co-investors5AM VenturesEpidarex CapitalF-Prime CapitalSanofi Ventures
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundEQTEQT Life SciencesForbion+2 more
NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.
FoodTech
Giuseppe Scionti(Founder)in
Co-investorsAurum Venture PartnersCarbonUnovis Asset ManagementVU Venture Partners
Nuage develops drug discovery technology targeting intrinsically disordered proteins in cancer, focusing on oncogenic transcription factors previously inaccessible to conventional drug discovery approaches.
AI & Machine LearningBiotechDeep Tech
Co-investorsBStartupAsabys Partners
The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.
Media & EntertainmentSports TechHà Nội, VN
Co-investorsAisling CapitalM VenturesNew Enterprise Associates (NEA)Sofinnova Ventures
BiotechPrinceton, US
Gerald Wisler(Executive Officer, Director)Christian Schade(Executive Officer)
BoardGraziano Seghezzi(Director)David Mott(Director)George Horner(Director)
Co-investorsNew Enterprise Associates (NEA)
P2 Science develops green chemistry platform technologies (including its PIOz ozonolysis and PICE polymerization processes) that convert renewable, plant-based oils into functional intermediates, specialty ingredients, and polymers.
BiotechCircular EconomyCleantechNew MaterialsWoodbridge, US
Paul Anastas(Co-founder)Patrick Foley(Co-founder & President)Neil A. Burns(Executive Officer, Director)Oihana Elizalde(Chief Executive Officer)Brian Chan(Chief Financial Officer)Kevin Gallagher(Director)
Co-investorsXeraya CapitalCircular Innovation FundConnecticut InnovationsEmerald Technology Ventures AgHG VenturesCycle Capital
Pi-Cardia develops non-implant-based, catheter-delivered devices for treating structural heart disease, including its ShortCut product for leaflet modification.
HardwareHealthtechMedical Devices
Erez Golan(Founder)in
Co-investorsAccelmed PartnersClal Biotechnology IndustriesIndaco Venture Partners
PinCell is a pre-clinical stage biotech company developing first-in-class anti-inflammatory therapies that target novel pathological pathways for dermatological diseases, with a focus on orphan skin disorders with high unmet medical need.
BiotechMedical Devices
Carlo Pincelli(CMO, Co-Founder, Co-Inventor)Antonino Amato(CEO)Brydon Bennett(CSO)
Co-investorsSofinnova Ventures
Prometheus Materials develops low-carbon cement and concrete technology, marketed as ProZERO, using algae-based biotechnology as a replacement for portland cement in ready-mix and construction applications.
CleantechConstruction TechNew MaterialsLongmont, US
Loren Burnett(President, CEO and Co-founder)inSherri Cook(Advisor and Co-founder)inMija Hubler(Engineering Advisor and Co-founder)inWil Srubar III(Technology Advisor and Co-founder)inJaclyn Gruber(Chief Marketing Officer)in
BoardJosko Bobanovic(Director)
Co-investorsAutodesk Foundation
ProQR Therapeutics develops RNA editing therapies for patients with genetic disorders through its proprietary Axiomer RNA editing platform.
BiotechHealthtech
Co-investorsInvivo Capital PartnersPontifax Venture Capital
Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.
BiotechHealthtechMedical Devices
Co-investorsBritish Patient CapitalForbionGilde Healthcare
Qorium develops cell-cultured leather grown from a single animal cell sample, producing uniform collagen sheets that integrate into existing tannery and leather-goods production processes.
BiotechCircular EconomyNew Materials
Co-investorsBrightlands Venture Partners
Recor Medical develops the Paradise ultrasound renal denervation system, a catheter-based therapy for reducing blood pressure in patients with hypertension.
BiotechHardwareHealthtechMedical DevicesPalo Alto, US
Antoine Papiernik(Executive Officer, Director)F. Thomas Watkins(Director)Kazumichi Kobayashi(Director)Jacques Seguin(Director)Frank Litvack(Director)Martin J. Waters(Executive Officer)
Co-investors415 Capital
Redona Therapeutics develops novel therapeutics targeting enzymes involved in the dysregulation of RNA and DNA processing and signaling, which contribute to serious diseases such as cancer and autoimmune conditions.
Biotech
Co-investorsAstellas Venture Management LLCOUP (Osage University Partners)
Provides pharmaceutical R&D services via the Cyto-Mine machine for single-cell analysis and characterisation.
Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedREDMILE
Synthace provides software and expert services that help life sciences teams design, automate, run, and analyze high dimensional, multifactorial biology experiments and produce contextualized, AI-ready datasets.
AI & Machine LearningBiotechSaaS
Co-investors11.2 CapitalFuture Planet CapitalHorizons VenturesUK Innovation & Science Seed FundAmadeus Capital PartnersSOSV
T-Therapeutics develops bispecific TCR-CD3 T cell engagers built on its OpTiMus TCR discovery platform to target previously undruggable intracellular targets.
BiotechDeep TechHealthtechCambridge, GB
Co-investorsF-Prime CapitalSanofi VenturesCambridge Innovation CapitalDigitalis Ventures
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye.
BiotechDigital HealthHealthtechLongevityMedical Devices
Co-investorsAdBio partnersF-Prime Capital
TISSIUM develops biomorphic polymer technology, including proprietary polymers, activation technologies, and delivery devices, to reconstruct damaged tissue and restore its function across multiple therapeutic areas.
BiotechDeep TechMedical DevicesNew Materials
Christophe Bancel(Co-founder & CEO)inMaria Pereira(Co-inventor of the technology; leads the Innovation Hub)in
Co-investorsCathay HealthKarista
Tulyp Medical develops the Tulyp System, an investigational pressure-controlled perfusion device with a microaxial pump cannula designed to restore blood flow to the leg in patients on femoral arterial support (VA-ECMO, IABP, pVAD) who are at risk of acute limb ischemia.
HardwareHealthtechMedical Devices
Co-investorsCTI Life Sciences Fund L.P.Pfizer Venture Investments
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Women-led biotech company engineering high-performance protein-based textile fibers for fashion with sustainable alternatives to synthetic fibers.
BiotechBrooklyn, US
Valentina Gomez(Executive Officer, Director)Theanne Schiros(Executive Officer)Chui-lian Lee(Executive Officer, Director)Chui-Lian Lee(Founder)in
BoardCorinna Chen(Director)inMichael Krel(Director)in
Co-investorsMaterial Impact
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
IPOs and acquisitions across the tracked portfolioAddex TherapeuticsNASDAQ: ADXNHemab TherapeuticsNASDAQ: COAGMaxcyteNASDAQ: MXCTQuince TherapeuticsNASDAQ: QNCX
Portfolio news
latest coverage across their companies
Galvanize · muonspace.com · Aug 20, 2026
ProQR · investing.com · Aug 20, 2026
Quince Therapeutics · investing.com · Aug 18, 2026
Mironid · eu-startups.com · Aug 7, 2026
Kidney · eu-startups.com · Aug 7, 2026
Addex Therapeutics · stocktitan.net · Jun 25, 2026
Frequently asked questions
- How many investments has Sofinnova Partners made?
- Sofinnova Partners has 168 tracked investments, including 7 dated in the last 24 months.
- What stage does Sofinnova Partners invest at?
- Sofinnova Partners invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What is Sofinnova Partners's typical check size?
- Sofinnova Partners typically writes checks of $540K – $27M.
- What sectors does Sofinnova Partners focus on?
- Sofinnova Partners focuses on AgTech, Biotech, Cleantech, Climate Tech, Deep Tech, Digital Health, FoodTech, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.
- Where is Sofinnova Partners located?
- Sofinnova Partners is headquartered in Paris, FR.
- Does Sofinnova Partners lead rounds?
- Yes, Sofinnova Partners leads investment rounds.
- Who does Sofinnova Partners co-invest with?
- Sofinnova Partners most often shares deals with Andera Partners, Indaco Venture Partners, Pfizer Venture Investments, among 132 tracked co-investors.
Media · Podcasts & interviews
featuring the teamAntoine Papiernik, Chairman of Sofinnova Partners, on Venture Capital in MedTech
State of MedTech · Antoine Papiernik
Images
Co-investors · 41
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
SV Health Investors is a healthcare-focused investment firm that invests across multiple stages, geographies and healthcare sectors.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
▶29 more co-investors
5AM VenturesBioGeneration VenturesApollo Health VenturesSonder CapitalLongwood FundAccess BiotechnologySOSVAtlas VentureUS Venture PartnersARCH Venture PartnersOrbiMedCambridge Innovation CapitalAbingworthDigitalis VenturesLeaps by BayerAbbVieUnovis Asset ManagementGV (Google Ventures)Canaan PartnersAtlantic Bridge VenturesMPM BioImpactPivotal Life SciencesAccess IndustriesSeventure PartnersLightstone VenturesIllumina VenturesWestlake Village BioPartnersJMI EquityAmzak Health
Firms observed investing alongside Sofinnova Partners, from public investor directories. Shared companies are the overlap with Sofinnova Partners's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner, backing emerging and established fund managers who invest in technology-focused Canadian companies.